Dynavax Technologies (NASDAQ:DVAX) had its target price increased by HC Wainwright from $23.00 to $28.00 in a research report issued on Wednesday, Price Targets.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 86.67% from the company’s previous close.
DVAX has been the topic of several other reports. Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Monday, November 8th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Monday, September 27th. Finally, William Blair reaffirmed a “hold” rating on shares of Dynavax Technologies in a research report on Friday, October 1st. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies currently has a consensus rating of “Buy” and an average target price of $19.67.
DVAX traded up $0.80 during trading hours on Wednesday, hitting $15.00. 1,632,910 shares of the company’s stock were exchanged, compared to its average volume of 3,898,832. Dynavax Technologies has a 1-year low of $4.36 and a 1-year high of $21.39. The stock’s 50-day moving average is $16.27 and its two-hundred day moving average is $14.29. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -42.86 and a beta of 1.40. The company has a quick ratio of 1.48, a current ratio of 1.61 and a debt-to-equity ratio of 3.26.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.29). Dynavax Technologies had a negative return on equity of 3.73% and a negative net margin of 14.60%. The business had revenue of $108.27 million for the quarter, compared to analyst estimates of $77.30 million. During the same quarter in the previous year, the company posted ($0.15) EPS. On average, equities research analysts anticipate that Dynavax Technologies will post 0.94 EPS for the current year.
In other news, COO David F. Novack sold 17,000 shares of the stock in a transaction dated Friday, October 1st. The shares were sold at an average price of $18.23, for a total value of $309,910.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO David F. Novack sold 3,000 shares of the stock in a transaction dated Thursday, October 7th. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $766,310 over the last ninety days. Insiders own 11.77% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Federated Hermes Inc. grew its stake in shares of Dynavax Technologies by 13.0% in the second quarter. Federated Hermes Inc. now owns 14,243,800 shares of the biopharmaceutical company’s stock valued at $140,301,000 after acquiring an additional 1,639,077 shares in the last quarter. Bain Capital Life Sciences Investors LLC grew its stake in Dynavax Technologies by 8.0% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 11,771,708 shares of the biopharmaceutical company’s stock worth $115,951,000 after buying an additional 875,935 shares in the last quarter. Vanguard Group Inc. grew its stake in Dynavax Technologies by 8.7% during the second quarter. Vanguard Group Inc. now owns 5,785,376 shares of the biopharmaceutical company’s stock worth $56,986,000 after buying an additional 463,533 shares in the last quarter. Marshall Wace LLP acquired a new stake in Dynavax Technologies during the third quarter worth about $98,295,000. Finally, Fisher Asset Management LLC grew its stake in Dynavax Technologies by 46.8% during the third quarter. Fisher Asset Management LLC now owns 3,323,777 shares of the biopharmaceutical company’s stock worth $63,850,000 after buying an additional 1,060,224 shares in the last quarter. Institutional investors and hedge funds own 85.15% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.